Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

EU, China approve Sarclisa + standard of care for MM

The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.

January 24, 2025

Vol.51 No.03

Clinical Trials & Tribulations

Chadi Nabhan: Why I wrote a book about cancer

Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their loved ones’ journeys. We have faced patients who took complementary therapies to an extreme; some to a point where they wouldn’t share what they were taking for fear that we might demand they stop.

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

In Brief

Jennifer Woyach named director of OSUCCC—James’s Division of Hematology

Jennifer A. Woyach, a blood cancer doctor and researcher who has been with Ohio State for more than 12 years, was named director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

YOU MAY BE INTERESTED IN

EU, China approve Sarclisa + standard of care for MM

Chadi Nabhan: Why I wrote a book about cancer

David Chung named director of clinical research at Northwell Health

Jennifer Woyach named director of OSUCCC—James’s Division of Hematology

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

Renew today!

Subscriber content

Never miss an issue!

Login